AGENDA
The Programme Faculty Panel is comprised of representatives from:
Lean Life Science, Cancer Research UK, MCRC, 4 global pharma companies, plus CRO partners.
Delivered by:
a unique team of seasoned oncology R&D professionals, commercial, and investment specialists.
ODP2 consists of three parts:
Part One
24 January 2023
Is an immersive one-day masterclass.
Part two
7 - 9 March 2023
Is a three-day deep dive into the highly successful Lean Life Science approach to developing oncology assets and securing investment, engaging directly with pharma and CRO experts.
Part Three
June - October 2023
By application, will see selected participants work closely with the partners to create and validate the integrated plans necessary to ensure successful development and attract potential funding.
PART 3 DEVELOP
JUNE – OCTOBER 2023
An intensive 5-month programme, supporting innovators or funders to become match fit to tell a compelling value story to investors.
ODP2 Part 3: DEVELOP will cover:
Gap analysis
- Validating line of sight with industry, academia and/or clinicians
- Exploring & validating commercial strategy & business model
- Engaging with CRO delivery partners
- Milestone setting
Project planning & costing
- Finance modelling and business valuation
- Strategic plans: Regulatory, Safety, Pre-clin/clin, IP, Valuation,
- Pitch development and practice
PART 2 AGENDA: DISCOVER
Delivered
7 - 9 March 2023
7th March
Voice of the customer:
What data do I need to see when considering in-licensing innovation?
- Talks from Pharma (Johnson & Johnson, Roche)
Anna Williamson
Executive Director, Global and UK Pharma Partnering, Roche
Richard Ward
Group Systems Director, AstraZeneca
Andrew Crockford
Director Early Innovation Partnering – Oncology, Johnson & Johnson
DELIVERY PARTNERSHIPS:
Hints and tips on how to access the UK’s publicly funded R&D delivery ecosystem
- A panel discussion with key stakeholders including universities, NHS, translational centres
Rahul Kapoor
Director of Health Tech, CPI
Helen Cole
Industry Partnerships Manager, NHSA
Lee Dunham
Cell & Gene Therapy Catapult
Sajni Haria
Business Development Manager, NIHR
Daniel Zamora
Health Innovation Manchester
Hints and tips on how to engage with Contract Research Organisations
- A biotech perspective
Nigel Brooks
Coach and Advisor, Lean Life Science
START WITH THE END IN MIND:
What it takes to develop an oncology innovation into a product
- Diagnostics, medical devices, digital/computational products
Jane Theaker
Chief Executive Officer, PbD Biotech
Paul Riley
Pharmaceutical & Life Sciences Consultant, Glasshouse Health
Critical external considerations for developing an oncology innovation into a product
- Intellectual property, regulatory, safety/tox considerations)
Lucy Padget
Patent Attorney & Partner, Alembia Intellectual Property
Bob Clay
Managing Director, Highbury Regulatory Science Limited
8th March
Case study of success
Talk from an academic on their entrepreneurial journey
Helen Philippou
Founder Director of LUNAC Therapeutics
Start with the end in mind
The importance of internal strategic planning
David Cook
Chief Scientific Officer, Blueberry Therapeutics
Nigel Brooks
Coach and Advisor, Lean Life Science
Voice of the customer
What do I need to see in a pitch to consider an innovation “investment ready”?
- Talk from a Venture Capital investor
Genghis Lloyd-Harris
Venture Partner, Abingworth
INTRODUCTION & USE OF LEAN INNOVATION TOOLS
- Introduction to lean innovation concepts, language & tools
- Opportunity to practice application of tools & use them to prepare for meet expert sessions on Day 3
Ned Wakeman
Founder & CEO, Lean Life Science
9th March
Meet the experts
Virtual partnering platform to secure 1:1 meetings with pharma companies, delivery partners (CROs) & Experts in Residence
PART 1 masterclass
Delivered
24 January 2023
overview of odp2
case studies of success
- PBD Biotech, Oncodrug, ImmTune Therapies
what good looks like
Investor Perspective
- Abingworth
Genghis Lloyd-Harris, Partner - SVLS
Alex Badamchi-Zadeh, Sr Investment Associate (CRUK Seed Fund) - OSE
Claire Brown, Partner
Pharma Perspective
- AstraZeneca
Shaun Grady, Snr VP Bus Dev - GSK
Jeremy Griggs, Senior Director Bus Dev - Novartis
Carla Bauer, Novartis NIBR BD&L S&E / Transactions
